Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WIN-Partners CoTSE:3183 +0.87%62 Return-on-Tangible-Equity is 10.48% as of Mar. 2026, which is 13% above its 10-year median of 9.26. GuruFocus rates TSE:3183 with a GF Score™ of 62/100 and a GF Value™ of 円1,503.56 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 112 Medical Distribution companies, WIN-Partners Co ranks better than 51.79% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. WIN-Partners Co's annualized net income for the quarter that ended in Mar. 2026 was 円2,358 Mil. WIN-Partners Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円22,498 Mil. Therefore, WIN-Partners Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 10.48%.
The historical rank and industry rank for WIN-Partners Co's Return-on-Tangible-Equity or its related term are showing as below:
TSE:3183'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 7.44 Med: 9.26 Max: 18.23
Current: 9.28
During the past 13 years, WIN-Partners Co's highest Return-on-Tangible-Equity was 18.23%. The lowest was 7.44%. And the median was 9.26%.
TSE:3183's Return-on-Tangible-Equity is ranked better than 51.79% of 112
companies
in the Medical Distribution industry
Industry Median: 8.155
vs TSE:3183: 9.28
WIN-Partners Co (TSE:3183) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
WIN-Partners Co Return-on-Tangible-Equity Related Terms
WIN-Partners Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for WIN-Partners Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3183 vs MCK, COR, CAH: Return-on-Tangible-Equity Comparison
For the Medical Distribution subindustry, WIN-Partners Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WIN-Partners Co Return-on-Tangible-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, WIN-Partners Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where WIN-Partners Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 10.48% mean?
WIN-Partners Co (TSE:3183) has a Return-on-Tangible-Equity of 10.48% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on WIN-Partners Co and its competitors. This is 13% above median its historical median of 9.26. Over the past decade, WIN-Partners Co's Return-on-Tangible-Equity has ranged from 7.44 to 18.23. According to the industry distribution chart, WIN-Partners Co ranks #54 out of 112 companies in the Medical Distribution industry, placing it in the top 48.2%.
Is WIN-Partners Co's Return-on-Tangible-Equity too high?
WIN-Partners Co's current Return-on-Tangible-Equity of 10.48% is 13% above median its 10-year median of 9.26. Over the past 10 years, this metric has ranged from a low of 7.44 to a high of 18.23. The Medical Distribution industry median Return-on-Tangible-Equity is 8.16. WIN-Partners Co's value of 10.48% is 28.5% above this industry median. Based on the distribution chart, WIN-Partners Co ranks #54 out of 112 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, WIN-Partners Co has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's Return-on-Tangible-Equity compare to MCK and COR?
According to the Medical Distribution industry distribution chart, WIN-Partners Co ranks #54 out of 112 companies for Return-on-Tangible-Equity. This puts WIN-Partners Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 8.16. WIN-Partners Co's value of 10.48% is 28.5% above this benchmark. Historically, WIN-Partners Co's own Return-on-Tangible-Equity has ranged from 7.44 to 18.23 over the past decade. While the company's 10-year median is 9.26 vs. the industry median of 8.16, WIN-Partners Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Distribution company?
The median Return-on-Tangible-Equity among Medical Distribution companies is 8.16, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WIN-Partners Co's current Return-on-Tangible-Equity of 10.48% is 28.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on WIN-Partners Co and its competitors. For the Medical Distribution industry, the median Return-on-Tangible-Equity is 8.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WIN-Partners Co's current Return-on-Tangible-Equity is 10.48%, which is 13% above median its own 10-year median of 9.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,503.56, compared to a current price of 円1,273.00 — trading 15.3% below its estimated fair value. The current Return-on-Tangible-Equity is 10.48%, which is 13% above median its 10-year median of 9.26 and 28.5% above the Medical Distribution industry median of 8.16. WIN-Partners Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current Return-on-Tangible-Equity is 10.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WIN-Partners Co (TSE:3183) Overvalued in 2026?
Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued.
The current stock price of 円1,273.00 is trading 15.3% below its estimated GF Value™ of 円1,503.56.
GuruFocus considers WIN-Partners Co to be Modestly Undervalued.
Key valuation signals for TSE:3183:
Return-on-Tangible-Equity: 10.48% (13% above median its 10-year median of 9.26)
GF Value™: 円1,503.56 vs. price of 円1,273.00 (15.3% below fair value)
Industry Position: 28.5% above the Medical Distribution median (#54 of 112)
No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
62GF Score
Get the complete analysis for TSE:3183
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3183 has been successfully added to your 
